An overview of localised corrosion inhibitor evaluation

The use of corrosion inhibitors is a flexible and economical option for localised corro-sion control. Unfortunately some high performance traditional inhibitors are toxic or environmentally unacceptable. Various new approaches of designing environmentally friendly “greener” inhibitors have been reported in the literature; however the perfor-mance of inhibitors in preventing localised forms of corrosion are often not sufficiently evaluated. An obstacle in new inhibitor evaluation is technological difficulties associ-ated with the assessment of localised corrosion. It is a challenging task to design effective experiments that are able to assess not only the tendency, but also the rates and the distribution of localised corrosion. This paper provides an overview of some recent progress in methodologies for evaluating localised corrosion inhibitors.

Carbon dioxide corrosion inhibition : an overview of recent research on new inhibitor development

Since the introduction of inhibitors to the oil and gas industry in the 1940’s, corrosion inhibition has played a key role in carbon dioxide (CO2) corrosion control. Major inhibitor discoveries occurred from the late 1940's to the late 1960's, followed by the refinement of formulations and the development of improved application methods. Over the past two to three decades, although some new derivatives of existing inhibitors such as amide, amine and imidazoline have been reported, there have been few if any discoveries of new CO2 corrosion inhibitors. In recent years, the development of environmentally friendly inhibitors and the inhibition of localised corrosion have become driving forces behind new advances in corrosion inhibitor technology. Recently a rare earth metal organic compound, lanthanum 4-hydroxy cinnamate has been found to be an efficient corrosion inhibitor for mild steel in CO2 containing aqueous media. A resorcinarene acid has been found to provide effective localised corrosion inhibition by promoting a random distribution of insignificant anodic currents. The advent of advanced scanning probe techniques and an electrochemical integrated multi-electrode array have facilitated the discovery of corrosion inhibitors. This paper provides a brief overview of recent progress in this field.

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: the BATMAN trial

Abstract:
Postmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone loss (AIBL) and fractures.

In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred and three postmenopausal women with early breast cancer (EBC) were enrolled (osteoporotic, n=25; osteopaenic, n=146; normal bone mineral density (BMD), n=126). Weekly alendronate (70 mg) treatment efficacy as triggered by the algorithm in preventing bone loss was evaluated. All patients received anastrozole (1 mg daily), calcium and vitamin D.

Results:
All osteoporotic patients received alendronate at baseline. Eleven out of the 146 (7.5%) osteopaenic patients commenced alendronate within 18 months of participation and eleven commenced after. One hundred and twenty four out of the 146 (84.9%) osteopaenic patients and all 126 with normal baseline BMD did not trigger the algorithm.

At three years, lumbar spine mean BMD increased (15.6%, p<0.01) in the osteoporotic group. BMD in the osteopaenic group with early intervention significantly increased at three years (6.3%, p=0.02). No significant change was seen in the late intervention group. No change was observed in those with osteopaenia without alendronate.

There was a significant drop in lumbar spine (−5.4%) and hip (−4.5%) mean BMD, in the normal BMD group, none of whom received alendronate.

Fracture data will be presented.

Conclusion:
In postmenopausal women with endocrine-responsive EBC, BMD improved over time when a bisphosphonate is administered with anastrozole in osteoporotic patients using an osteoporosis schedule. Subjects with normal baseline BMD experienced the greatest BMD loss, although none became osteoporotic.